AgomAb Therapeutics NV (AGMB) Receivables (2024 - 2025)
Agomab Therapeutics (AGMB) reported Receivables of $7.14 million for Q4 2025, up 113.1% from $3.35 million a year earlier.
Powered by 
Analysis
AgomAb Therapeutics NV (AGMB) Receivables (2024 - 2025) Analysis & Trends
At the end of FY2025, Agomab Therapeutics posted Receivables of $6.93 million, up 104.2% from FY2024.
- By year, Receivables came in at $3.39 million in FY2024.
Peer Set
Peer Comparison
API Access
AgomAb Therapeutics NV Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=AGMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "AGMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=AGMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();